Teprotumumab is a human monoclonal antibody that acts as an inhibitor of the insulin-like growth factor 1 receptor (IGF-1R). This antibody specifically targets and binds to the extracellular α-subunit domain of IGF-1R, which is crucial for its ligand-binding activity. By doing so, Teprotumumab effectively blocks the receptor's interaction with its ligands, thereby inhibiting downstream signaling pathways. The antibody has been shown to impede both thyroid-stimulating hormone (TSH) and IGF-1 mediated actions in fibrocytes, leading to a reduction in TSH-dependent interleukin-6 (IL-6) and interleukin-8 (IL-8) expression, as well as Akt phosphorylation. Teprotumumab is primarily utilized in research focused on thyroid-associated ophthalmopathy, providing a valuable tool for studying the pathophysiology and potential therapeutic interventions for this condition.
Teprotumumab is a human monoclonal antibody that acts as an inhibitor of the insulin-like growth factor 1 receptor (IGF-1R). This antibody specifically targets and binds to the extracellular α-subunit domain of IGF-1R, which is crucial for its ligand-binding activity. By doing so, Teprotumumab effectively blocks the receptor's interaction with its ligands, thereby inhibiting downstream signaling pathways. The antibody has been shown to impede both thyroid-stimulating hormone (TSH) and IGF-1 mediated actions in fibrocytes, leading to a reduction in TSH-dependent interleukin-6 (IL-6) and interleukin-8 (IL-8) expression, as well as Akt phosphorylation. Teprotumumab is primarily utilized in research focused on thyroid-associated ophthalmopathy, providing a valuable tool for studying the pathophysiology and potential therapeutic interventions for this condition.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
Please check COA/MSDS for correct molecular weight.
Calculate the dilution required to prepare a stock solution.This equation is commonly abbreviated as: C1V1 = C2V2
Frequently Asked Questions
What are Biosimilar Antibodies?
Biosimilar antibodies are research-grade recombinant antibodies designed to closely resemble approved therapeutic antibodies in terms of amino acid sequence, structural characteristics, and biological activity. These antibodies are generated using recombinant expression technologies and retain the same variable regions as their corresponding reference therapeutics, thereby preserving target specificity and binding affinity. Owing to these properties, biosimilar antibodies serve as reliable and cost-effective research reagents for applications in drug discovery, pharmacological studies, and basic biomedical research.
Research-grade biosimilar antibodies have been successfully expressed and functionally validated against a wide range of widely studied targets. These antibodies can be directly utilized as positive control reagents in drug discovery programs, as well as reference tools for rapid verification of the biological functions of target proteins in biochemical and cellular assays.
